Cephalexin: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 24: Line 24:
'''| [[Cephalexin adverse reactions|Adverse Reactions]]'''
'''| [[Cephalexin adverse reactions|Adverse Reactions]]'''
'''| [[Cephalexin overdosage|Overdosage]]'''
'''| [[Cephalexin overdosage|Overdosage]]'''
'''| [[Cephalexin clinical studies|Clinical Studies]]'''
'''| [[Cephalexin dosage and administration|Dosage and Administration]]'''
'''| [[Cephalexin dosage and administration|Dosage and Administration]]'''
'''| [[Cephalexin how supplied|How Supplied]]'''
'''| [[Cephalexin how supplied|How Supplied]]'''

Revision as of 16:39, 2 January 2014

Cephalexin
CEPHALEXIN®,KEFLEX® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Overview

Cephalexin (INN) or more commonly cephalexin /ˌsɛfəˈlɛksɨn/ is a first-generation cephalosporin antibiotic introduced in 1967 by Eli Lilly and Company.[2][3] It is an orally administered agent with a similar antimicrobial spectrum to the intravenous agents cefalotin and cefazolin. It was first marketed as Keflex (Lilly), and is marketed under several other trade names.

Category

Cephalosporins, first generation.

US Brand Names

CEPHALEXIN®,KEFLEX®

Dosing and Administration

Cephalexin tablets, capsules and oral suspension are administered orally.

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages


References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050405s097lbl.pdf